1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2016”

DelveInsight’s, “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2016”, report provides comprehensive insight and understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. With the emerging immune-oncology therapeutic strategy for T-cell-mediated diseases, companies are focusing on the development of immune-check inhibitors like Lag-3, OX-40 and TIM-3 inhibitors which gained importance in recent years.

Report highlights that majorly development is seen for Lag-3 antagonist, with the lead drug of Prima BioMed in Phase II stage of development. In case of OX-40 agonists close to 4 drugs are in Phase I stage of development with AstraZeneca having its 2 drug candidates in Phase I. Majorly drug candidates are seen in early stages of development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.
The Report gives insights on 33+ products with 20+ different technologies. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

Scope

-DelveInsight’s report provides a LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Landscape across the globe
-The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
-Coverage of the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
-The report reviews key players involved in the therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists and also provide company profiling
-Pipeline products coverage based on various stages of development from NDA filings to discovery.
-Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reason to Buy

- Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists
- Identify different type of technologies involved in the development of the therapeutics.
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Track your competitors and develop strategic initiatives to support your drug development activities.
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline in-depth
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets

Table Of Contents

“LAG-3 Antagonists, TIM-3 Antagonists and OX40 Agonists-Pipeline Insights, 2016”
Table of contents:
LAG-3, TIM-3 and OX40 Overview
Total Products Overview
Products Share by Clinical Stages
Products Share by Pre-clinical and Discovery Stages
LAG-3 Antagonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
TIM-3 Antagonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
OX40 Agonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Additional Information
Discontinued Products
Companies Involved in Therapeutics Development
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of tables

Table 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2016
Table 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2016
Table 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2016
Table 4: Number of Products under Development for LAG-3 Antagonists, 2016
Table 5: Number of Products under Development by Companies, 2016
Table 6: Mid Stage Products (Phase II), 2016
Table 7: Early Stage Products (Phase I and IND), 2016
Table 8: Discovery and Pre-clinical Stage Products, 2016
Table 9: Assessment by Monotherapy Products for LAG-3 Antagonists, 2016
Table 10: Assessment by Combination Products for LAG-3 Antagonists, 2016
Table 11: Assessment by Route of Administration for LAG-3 Antagonists, 2016
Table 12: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016
Table 13: Assessment by Molecule Type for LAG-3 Antagonists, 2016
Table 14: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2016
Table 15: Number of Products under Development for TIM-3 Antagonists, 2016
Table 16: Number of Products under Development by Companies, 2016
Table 17: Early Stage Products (Phase I and IND), 2016
Table 18: Discovery and Pre-clinical Stage Products, 2016
Table 19: Assessment by Monotherapy Products for TIM-3 Antagonists, 2016
Table 20: Assessment by Route of Administration for TIM-3 Antagonists, 2016
Table 21: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016
Table 22: Assessment by Molecule Type for TIM-3 Antagonists, 2016
Table 23: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2016
Table 24: Number of Products under Development for OX40 Agonists, 2016
Table 25: Number of Products under Development by Companies, 2016
Table 26: Early Stage Products (Phase I and IND), 2016
Table 27: Discovery and Pre-clinical Stage Products, 2016
Table 28: Assessment by Monotherapy Products for OX40 Agonists, 2016
Table 29: Assessment by Route of Administration for OX40 Agonists, 2016
Table 30: Assessment by Stage and Route of Administration for OX40 Agonists, 2016
Table 31: Assessment by Molecule Type for OX40 Agonists, 2016
Table 32: Assessment by Stage and Molecule Type for OX40 Agonists, 2016
Table 33: Discontinued Products, 2016
Table 34: Companies Involved in Therapeutic Development, 2016

List of figures:

Figure 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2016 (%)
Figure 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2016 (%)
Figure 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2016 (%)
Figure 4: Number of Products under Development for LAG-3 Antagonists, 2016
Figure 5: Mid Stage Products (Phase II), 2016
Figure 6: Early Stage Products (Phase I and IND), 2016
Figure 7: Discovery and Pre-clinical Stage Products, 2016
Figure 8: Assessment by Monotherapy Products for LAG-3 Antagonists, 2016
Figure 9: Assessment by Combination Products for LAG-3 Antagonists, 2016
Figure 10: Assessment by Route of Administration for LAG-3 Antagonists, 2016
Figure 11: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016
Figure 12: Assessment by Molecule Type for LAG-3 Antagonists, 2016
Figure 13: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2016
Figure 14: Number of Products under Development for TIM-3 Antagonists, 2016
Figure 15: Early Stage Products (Phase I and IND), 2016
Figure 16: Discovery and Pre-clinical Stage Products, 2016
Figure 17: Assessment by Monotherapy Products for TIM-3 Antagonists, 2016
Figure 18: Assessment by Combination Products for TIM-3 Antagonists, 2016
Figure 19: Assessment by Route of Administration for TIM-3 Antagonists, 2016
Figure 20: Assessment by Stage and Route of Administration for TIM-3 Antagonists, 2016
Figure 21: Assessment by Molecule Type for TIM-3 Antagonists, 2016
Figure 22: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2016
Figure 23: Number of Products under Development for OX-40 Agonists, 2016
Figure 24: Early Stage Products (Phase I and IND), 2016
Figure 25: Discovery and Pre-clinical Stage Products, 2016
Figure 26: Assessment by Monotherapy Products for OX40 Agonists, 2016
Figure 27: Assessment by Route of Administration for OX40 Agonists, 2016
Figure 28: Assessment by Stage and Route of Administration for OX40 Agonists, 2016
Figure 29: Assessment by Molecule Type for OX40 Agonists, 2016
Figure 30: Assessment by Stage and Molecule Type for OX40 Agonists, 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.